AC T01420
XX
ID T01420
XX
DT 03.04.1995 (created); ewi.
DT 11.12.2013 (updated); mkl.
CO Copyright (C), QIAGEN.
XX
FA C/EBPbeta-LIP
XX
SY C/EBPbeta(p20); C/EBPbeta3; LIP; liver-enriched inhibitory protein; p20(C/EBPbeta); p20C/EBPbeta.
XX
OS rat, Rattus norvegicus
OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; rodentia; myomorpha; muridae; murinae
XX
GE G013627 Cebpb.
XX
CL C0008; bZIP.
XX
SZ 145 AA; 15.6 kDa (cDNA) (calc.), 20 kDa (SDS)
XX
SQ MAAGFPFALRAYLGYQATPSGSSGSLSTSSSSSPPGTPSPADAKAAPAACFAGPPAAPAK
SQ AKAKKAVDKLSDEYKMRRERNNIAVRKSRDKAKMRNLETQHKVLELTAENERLQKKVEQL
SQ SRELSTLRNLFKQLPEPLLASAGHC
XX
FT 69 133 
SM00338; brlzneu.
FT 70 123 
PF07716; Basic region leucine zipper.
FT 71 134 
PS50217; BZIP.
XX
SF lacks the N-terminal transactivation domain in comparison with p35 isoform T00459, shares the C-terminal DBD and dimerization domains;
SF generated from the same mRNA as LAP (C/EBPbeta) by a leaky scanning mechanism;
SF pI 10.61 (calc.) [1];
SF half-saturation of DNA-binding at 0.44 nM, thus lower than for C/EBPbeta [1];
SF C-terminal region is sufficient to mediate interactions with A-box of Elk-1 [4];
XX
CP enriched in liver cells [1]; low in liver, high levels in fibroblasts, lymphocytes [3] [1] [3].
XX
FF transcriptional repressor;
FF attenuates transcriptional stimulation by C/EBPbeta, probably due to its higher DNA-binding affinity [1];
FF cellular ratio of C/EBPbeta / LIP is essential for activation;
FF increases 5-fold during liver differentiation [1];
FF in contrast to full-length C/EBPbeta, it does not arrest hepatoma cell cycle progression and even antagonizes C/EBPbeta in doing so [2];
FF enrichment in fibroblasts over the longer C/EBPbeta isoforms is (partially) due to an extended-half-life [3];
XX
IN T00459 C/EBPbeta-FL; rat, Rattus norvegicus.
IN T02105 C/EBPbeta-LAP; rat, Rattus norvegicus.
IN T00250 Elk-1; human, Homo sapiens.
XX
MX M00109 V$CEBPB_01.
MX M00117 V$CEBPB_02.
MX M07315 V$CEBPB_Q3.
MX M01896 V$CEBPB_Q6.
MX M00912 V$CEBP_Q2_01.
MX M00770 V$CEBP_Q3.
XX
BS R24131.
BS R00089.
BS R58214.
BS R58215.
BS R58216.
BS R58217.
BS R58218.
BS R58222.
BS R58225.
BS R58226.
BS R58228.
BS R58229.
BS R58230.
BS R58231.
BS R58237.
BS R28689.
BS R01344.
XX
DR TRANSPATH: MO000025659.
XX
RN [1]; RE0002865.
RX PUBMED: 1934061.
RA Descombes P., Schibler U.
RT A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA
RL Cell 67:569-579 (1991).
RN [2]; RE0007044.
RX PUBMED: 7906646.
RA Buck M., Turler H., Chojkier M.
RT LAP (NF-IL-6), a tissue-specific transcriptional activator, is an inhibitor of hepatoma cell proliferation
RL EMBO J. 13:851-860 (1994).
RN [3]; RE0007055.
RX PUBMED: 8007984.
RA Sears R. C., Sealy L.
RT Multiple forms of C/EBP beta bind the EFII enhancer sequence in the Rous sarcoma virus long terminal repeat
RL Mol. Cell. Biol. 14:4855-4871 (1994).
RN [4]; RE0016725.
RX PUBMED: 11151091.
RA Hanlon M., Bundy L. M., Sealy L.
RT C/EBPBeta and Elk-1 synergistically transactivate the c-fos serum response element.
RL BMC Cell Biol. 1:2 (2000).
XX
//